spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

IONTAS to Generate Antibodies using Mammalian Display Technology for a Global Biopharma

IONTAS to generate antibodies with favourable, binding and expression properties using their Mammalian Display Antibody Discovery Platform

Cambridge, UK, 22 January 2018: IONTAS Limited (IONTAS), a leader in the discovery and optimisation of fully human antibodies, announced today that it has signed an agreement with Sanofi to discover antibodies using IONTAS’ proprietary Mammalian Display Technology.

IONTAS’ platform allows for the construction of large libraries of monoclonal cell lines each displaying a different IgG-formatted antibody on the cell surface. Novel binders can be isolated from the libraries by using fluorescence-activated cell sorting on the basis of antigen binding. Importantly, the system also has the potential to identify clones with development liabilities, such as self-aggregation, during the initial discovery phase.

Dr John McCafferty, CEO at IONTAS, commented: “Historically the consideration of developability issues have been addressed after selection of drug lead molecules. Our Mammalian Display Platform not only allows direct screening of millions of clones for binding affinity and specificity, but also has the potential for early identification of developability issues such as product precipitation. Such issues can derail product development resulting in significant losses in time and money.”

ENDS

IONTAS Ltd
Neil Butt, Chief Business Officer
Tel: +44 1223 750801
bd@iontas.co.uk

Zyme Communications
Lorna Cuddon
Tel: +44 (0)1223 968 920
lorna.cuddon@zymecommunications.com

About IONTAS
www.iontas.co.uk
IONTAS is a biotechnology company focused on antibody discovery and cutting-edge technology development. IONTAS offers services for antibody discovery using Phage Display Technology; and the supply of bespoke phage display libraries. In addition, IONTAS has developed proprietary antibody discovery platforms including Mammalian Display where full IgG antibodies are expressed in the context of a mammalian cell thereby allowing selection based on function, stability, expression and developability; and, KnotBody technology which facilitates the targeting of antibodies to ion channels, GPCRs and proteases.
 
Print this page
Send to a friend
   
spacer
News and Press Releases

Wire it with pride with Teknomeks latest modular storage options

Teknomek has extended its modular shelving range to offer customers more options to make optimal use of the storage space available to them. The hygienic units are built from 304 grade stainless steel and feature wire shelving, which does not interrupt air circulation and prevents from dust settling.
More info >>


White Papers

Industry Events

PDA Universe of Pre-Filled Syringes and Injection Devices

8 October - 9 November 2018, Loews Royal Pacific, Orlando, FL

At the 2018 PDA Universe of Pre-filled Syringes and Injection Devices,industry and regulatory experts will share experiences, new developments, regulatory considerations, challenges, and industry trends and best practices. This is a must-attend event for all industry professionals involved in the development, manufacturing, testing, or marketing of pre-filled syringes and injection devices.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement